

**SENATE
STATE OF MINNESOTA
NINETY-THIRD SESSION**

S.F. No. 3727

(SENATE AUTHORS: MANN)

DATE
02/15/2024

D-PG

Introduction and first reading
Referred to Health and Human Services

OFFICIAL STATUS

1.1 A bill for an act
1.2 relating to health; amending opiate product manufacturer reporting requirements;
1.3 amending opiate product registration fee determination process; amending
1.4 Minnesota Statutes 2022, section 151.066, subdivisions 1, 2, 3.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. Minnesota Statutes 2022, section 151.066, subdivision 1, is amended to read:

1.7 Subdivision 1. **Definitions.** (a) For purposes of this section, the following terms have
1.8 the meanings given to them in this subdivision.

1.9 (b) "Manufacturer" means a manufacturer licensed under section 151.252 ~~that is engaged~~
1.10 ~~in the manufacturing of an opiate~~, excluding those exclusively licensed to manufacture
1.11 medical gas.

1.12 (c) "Opiate" means any opiate-containing controlled substance listed in section 152.02,
1.13 subdivisions 3 to 5, that is distributed, delivered, sold, or dispensed into or within this state.

1.14 (d) "Third-party logistics provider" means a third-party logistics provider licensed under
1.15 section 151.471.

1.16 (e) "Wholesaler" means a wholesale drug distributor licensed under section 151.47 ~~that~~
1.17 ~~is engaged in the wholesale drug distribution of an opiate~~, excluding those exclusively
1.18 licensed to distribute medical gas.

1.19 Sec. 2. Minnesota Statutes 2022, section 151.066, subdivision 2, is amended to read:

1.20 Subd. 2. **Reporting requirements.** (a) By March 1 of each year, beginning March 1,
1.21 2020, each manufacturer and each wholesaler must report to the board every sale, delivery,

2.1 or other distribution within or into this state of any opiate that is made to any practitioner,
2.2 pharmacy, hospital, veterinary hospital, or other person who is permitted by section 151.37
2.3 to possess controlled substances for administration or dispensing to patients that occurred
2.4 during the previous calendar year. Reporting must be in the automation of reports and
2.5 consolidated orders system format unless otherwise specified by the board. If no reportable
2.6 distributions occurred for a given year, notification must be provided to the board in a
2.7 manner specified by the board. If a manufacturer or wholesaler fails to provide information
2.8 required under this paragraph on a timely basis, the board may assess an administrative
2.9 penalty of \$500 per day. This penalty shall not be considered a form of disciplinary action.

2.10 (b) By March 1 of each year, beginning March 1, 2020, each owner of a pharmacy with
2.11 at least one location within this state must report to the board any intracompany delivery
2.12 or distribution into this state, of any opiate, to the extent that those deliveries and distributions
2.13 are not reported to the board by a licensed wholesaler owned by, under contract to, or
2.14 otherwise operating on behalf of the owner of the pharmacy. Reporting must be in the
2.15 manner and format specified by the board for deliveries and distributions that occurred
2.16 during the previous calendar year. The report must include the name of the manufacturer
2.17 or wholesaler from which the owner of the pharmacy ultimately purchased the opiate, and
2.18 the amount and date that the purchase occurred.

2.19 (c) By March 1 of each year, beginning March 1, 2024, each third-party logistics provider
2.20 must report to the board any delivery or distribution into this state of any opiate, to the
2.21 extent that those deliveries and distributions are not reported to the board by a licensed
2.22 wholesaler or manufacturer. Reporting must be in the manner and format specified by the
2.23 board for deliveries and distributions that occurred during the previous calendar year.

2.24 Sec. 3. Minnesota Statutes 2022, section 151.066, subdivision 3, is amended to read:

2.25 Subd. 3. **Determination of an opiate product registration fee.** (a) The board shall
2.26 annually assess an opiate product registration fee on any manufacturer of an opiate ~~that~~
2.27 whose opiate product is annually sells, delivers, or distributes an opiate sold, delivered, or
2.28 distributed within or into the state in a quantity of 2,000,000 or more units as reported to
2.29 the board under subdivision 2.

2.30 (b) For purposes of assessing the annual registration fee under this section and
2.31 determining the number of opiate units a manufacturer sold, delivered, or distributed within
2.32 or into the state, the board shall not consider any opiate that is used for substance use disorder
2.33 treatment with medications for opioid use disorder.

3.1 (c) The annual registration fee for each manufacturer meeting the requirement under
3.2 paragraph (a) is \$250,000.

3.3 (d) In conjunction with the data reported under this section, and notwithstanding section
3.4 152.126, subdivision 6, the board may use the data reported under section 152.126,
3.5 subdivision 4, to determine which manufacturers meet the requirement under paragraph (a)
3.6 and are required to pay the registration fees under this subdivision.

3.7 (e) By April 1 of each year, beginning April 1, 2020, the board shall notify a manufacturer
3.8 that the manufacturer meets the requirement in paragraph (a) and is required to pay the
3.9 annual registration fee in accordance with section 151.252, subdivision 1, paragraph (b).

3.10 (f) A manufacturer may dispute the board's determination that the manufacturer must
3.11 pay the registration fee no later than 30 days after the date of notification. However, the
3.12 manufacturer must still remit the fee as required by section 151.252, subdivision 1, paragraph
3.13 (b). The dispute must be filed with the board in the manner and using the forms specified
3.14 by the board. A manufacturer must submit, with the required forms, data satisfactory to the
3.15 board that demonstrates that the assessment of the registration fee was incorrect. The board
3.16 must make a decision concerning a dispute no later than 60 days after receiving the required
3.17 dispute forms. If the board determines that the manufacturer has satisfactorily demonstrated
3.18 that the fee was incorrectly assessed, the board must refund the amount paid in error.

3.19 (g) For purposes of this subdivision, a unit means the individual dosage form of the
3.20 particular drug product that is prescribed to the patient. One unit equals one tablet, capsule,
3.21 patch, syringe, milliliter, or gram.

3.22 (h) For the purposes of this subdivision, an opiate's units will be assigned to the
3.23 manufacturer holding the New Drug Application (NDA) or Abbreviated New Drug
3.24 Application (ANDA), as listed by the United States Food and Drug Administration.